# A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma

> **NCT04074330** · PHASE1,PHASE2 · TERMINATED · sponsor: **Takeda** · enrollment: 38 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** TAK-981
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04074330
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-15
- **Primary completion:** 2023-04-26
- **Final completion:** 2023-04-26
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** Enrolment Challenges
- **Last updated:** 2024-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04074330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04074330, "A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04074330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*